Facing a tough business climate and constraints on pharma spending, GeneProt has decided to modify its partnering strategy to appeal to pharma and biotech companies unwilling to spend on the scale of its current partner Novartis, which signed a deal valued at $84 million with the company a year and a half ago, GeneProt officials told ProteoMonitor last week.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.